The FDA has approved Gilead’s combination drug Descovy for HIV prophylaxis in the US, offering a way of cutting the risk of sexually acquired infection with an improved safety profile compa
GSK’s ViiV Healthcare joint venture has announced data backing an injection taken that can suppress the HIV virus even if it is taken only six times a year, instead of every month.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
